Skip to main content
Erschienen in: Heart and Vessels 5/2015

01.09.2015 | Original Article

Risk factors for rehospitalization in heart failure with preserved ejection fraction compared with reduced ejection fraction

verfasst von: Masahiko Setoguchi, Yuji Hashimoto, Taro Sasaoka, Takashi Ashikaga, Mitsuaki Isobe

Erschienen in: Heart and Vessels | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Although there have been several studies regarding heart failure with preserved ejection fraction (HFpEF), investigations of the risk factors for readmission of Japanese patients with HFpEF remain scarce. Therefore, our goal was to identify the risk factors for readmission of Japanese patients with heart failure (HF), particularly those with HFpEF. We analyzed 310 patients who were hospitalized for the first time with HF. Preserved EF was defined EF ≥50 %, and reduced EF (rEF) was EF <50 %. The study endpoint was readmission for HF after discharge. Medical history, vital signs, electrocardiograms, chest radiographs, blood tests and echocardiograms were compared between patients with HFpEF and with HFrEF. Among the 142 patients who had HFpEF, 43 reached the endpoint within 1 year. Multivariate analysis revealed depression (HR: 7.185), high brain natriuretic peptide (BNP) levels at discharge (HR: 1.003), and dilated inferior vena cava (HR: 1.100) as independent risk factors for readmission. In contrast, 39 of the 168 patients with HFrEF reached the endpoint. Risk factors for readmission of HFrEF patients were low sodium (HR: 0.856), high blood urea nitrogen (HR: 1.045), high BNP levels at discharge (HR: 1.003) and absence of beta-blocker prescription (HR: 0.395). In conclusion, our study suggests that the predictors of HF readmission differ between HFpEF and HFrEF patients.
Literatur
1.
Zurück zum Zitat Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, Kato N, Takeshita A, Tsutsui H (2009) Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). Circ J 73:1893–1900CrossRefPubMed Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, Kato N, Takeshita A, Tsutsui H (2009) Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). Circ J 73:1893–1900CrossRefPubMed
2.
Zurück zum Zitat Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, Shirato K, The CHART investigators (2004) Analysis of chronic heart failure registry in the Tohoku district; third year follow-up. Circ J 68:427–434CrossRefPubMed Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, Shirato K, The CHART investigators (2004) Analysis of chronic heart failure registry in the Tohoku district; third year follow-up. Circ J 68:427–434CrossRefPubMed
3.
Zurück zum Zitat Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259CrossRefPubMed Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259CrossRefPubMed
4.
Zurück zum Zitat Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC (2012) Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126:65–75CrossRefPubMed Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC (2012) Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126:65–75CrossRefPubMed
5.
Zurück zum Zitat Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XHT, Deswal A (2012) Impact of noncardiac co-morbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59:998–1005CrossRefPubMed Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XHT, Deswal A (2012) Impact of noncardiac co-morbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59:998–1005CrossRefPubMed
6.
Zurück zum Zitat Kitzman DW (2012) Outcomes in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 59:1006–1007CrossRefPubMed Kitzman DW (2012) Outcomes in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 59:1006–1007CrossRefPubMed
7.
Zurück zum Zitat Lee DS, Gona P, Albano I, Larson MG, Benjamin EJ, Levy D, Kannel WB, Vasan RS (2011) A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 4:36–43CrossRefPubMedCentralPubMed Lee DS, Gona P, Albano I, Larson MG, Benjamin EJ, Levy D, Kannel WB, Vasan RS (2011) A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 4:36–43CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Marechaux S, Six-Carpentier MM, Bouabdallaoui N, Montaigne D, Bauchart JJ, Mouquet F, Auffray JL, Tourneau TL, Asseman P, LeJemtel TH, Ennezat PV (2011) Prognostic importance of co-morbidities in heart failure with preserved left ventricular ejection fraction. Heart Vessels 26:313–320CrossRefPubMed Marechaux S, Six-Carpentier MM, Bouabdallaoui N, Montaigne D, Bauchart JJ, Mouquet F, Auffray JL, Tourneau TL, Asseman P, LeJemtel TH, Ennezat PV (2011) Prognostic importance of co-morbidities in heart failure with preserved left ventricular ejection fraction. Heart Vessels 26:313–320CrossRefPubMed
9.
Zurück zum Zitat McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446CrossRefPubMed McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446CrossRefPubMed
10.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 33:1787–1847CrossRefPubMed McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 33:1787–1847CrossRefPubMed
11.
Zurück zum Zitat Radloff LS (1977) The CES-D scale; a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRef Radloff LS (1977) The CES-D scale; a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRef
12.
Zurück zum Zitat O’Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC (2008) Predictors of mortality after discharge in patients with heart failure: an analysis from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J 156:662–673CrossRefPubMed O’Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC (2008) Predictors of mortality after discharge in patients with heart failure: an analysis from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J 156:662–673CrossRefPubMed
13.
Zurück zum Zitat Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski Y, PEP-CHF investigators (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338–2345CrossRefPubMed Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski Y, PEP-CHF investigators (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338–2345CrossRefPubMed
14.
Zurück zum Zitat Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees (2003) Effect of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-PRESERVED trial. Lancet 362:777–781CrossRefPubMed Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees (2003) Effect of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-PRESERVED trial. Lancet 362:777–781CrossRefPubMed
15.
Zurück zum Zitat Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467CrossRefPubMed Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467CrossRefPubMed
16.
Zurück zum Zitat Zhou J, Shi H, Zhang J, Lu Y, Fu M, Ge J (2010) Rationale and design of theβ-blocker in heart failure with normal left ventricular ejection fraction (β-PRESERVE) study. Eur J Heart Fail 12:181–185CrossRefPubMed Zhou J, Shi H, Zhang J, Lu Y, Fu M, Ge J (2010) Rationale and design of theβ-blocker in heart failure with normal left ventricular ejection fraction (β-PRESERVE) study. Eur J Heart Fail 12:181–185CrossRefPubMed
17.
Zurück zum Zitat Hori M, Kitabatake A, Tsutsui H, Okamoto H, Shirato K, Nagai R, Izumi T, Yokoyama H, Yasumura Y, Ishida Y, Matsuzaki M, Oki T, Sekiya M, J-DHF Program Committee (2005) Rationale and design of a randomized tiral to assess the effect of β-blocker in diastolic heart failure: Japanese diastolic heart failure study (J-DHF). J Card Fail 11:542–547CrossRefPubMed Hori M, Kitabatake A, Tsutsui H, Okamoto H, Shirato K, Nagai R, Izumi T, Yokoyama H, Yasumura Y, Ishida Y, Matsuzaki M, Oki T, Sekiya M, J-DHF Program Committee (2005) Rationale and design of a randomized tiral to assess the effect of β-blocker in diastolic heart failure: Japanese diastolic heart failure study (J-DHF). J Card Fail 11:542–547CrossRefPubMed
18.
Zurück zum Zitat Konishi M, Haraguchi G, Ohigashi H, Sasaoka T, Yoshikawa S, Inagaki H, Ashikaga T, Isobe M (2012) Progression of hyponatremia is associated with increased cardiac mortality in patients hospitalized for acute decompensated heart failure. J Card Fail 8:620–625CrossRef Konishi M, Haraguchi G, Ohigashi H, Sasaoka T, Yoshikawa S, Inagaki H, Ashikaga T, Isobe M (2012) Progression of hyponatremia is associated with increased cardiac mortality in patients hospitalized for acute decompensated heart failure. J Card Fail 8:620–625CrossRef
19.
Zurück zum Zitat Klein L, Massie BM, Leimberger JD, O’Connor CM, Plna IL, Adams KF Jr, Cliff RM, Gheorghiade M (2008) Admission or change in renal function during hospitalization for worsening heart failure predict post discharge survival: results from the outcomes of a progressive trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). Circ Heart Fail 1:25–33CrossRefPubMed Klein L, Massie BM, Leimberger JD, O’Connor CM, Plna IL, Adams KF Jr, Cliff RM, Gheorghiade M (2008) Admission or change in renal function during hospitalization for worsening heart failure predict post discharge survival: results from the outcomes of a progressive trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). Circ Heart Fail 1:25–33CrossRefPubMed
20.
Zurück zum Zitat Kociol RD, Horton JR, Fonarow FC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF (2011) Admission, discharge, or change in b-type natriuretic peptide and long-term outcomes. Data from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) linked to medicare claims. Circ Heart Fail 4:628–636CrossRefPubMedCentralPubMed Kociol RD, Horton JR, Fonarow FC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF (2011) Admission, discharge, or change in b-type natriuretic peptide and long-term outcomes. Data from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) linked to medicare claims. Circ Heart Fail 4:628–636CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, Demets DL (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658CrossRefPubMed Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, Demets DL (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658CrossRefPubMed
22.
Zurück zum Zitat Kallistratos MS, Poulimenos LE, Pavlidis AN, Dritsas A, Laoutaris ID, Manolis AJ, Cokkinos DV (2012) Prognostic significance of blood pressure response to exercise in patients with systolic heart failure. Heart Vessels 27:46–52CrossRefPubMed Kallistratos MS, Poulimenos LE, Pavlidis AN, Dritsas A, Laoutaris ID, Manolis AJ, Cokkinos DV (2012) Prognostic significance of blood pressure response to exercise in patients with systolic heart failure. Heart Vessels 27:46–52CrossRefPubMed
23.
Zurück zum Zitat Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ (2006) Depression in heart failure. A meta-analysis review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 48:1527–1537CrossRefPubMed Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ (2006) Depression in heart failure. A meta-analysis review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 48:1527–1537CrossRefPubMed
24.
Zurück zum Zitat Joynt KE, Whellan DJ, O’Connor CM (2004) Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Card Fail 10:258–271CrossRefPubMed Joynt KE, Whellan DJ, O’Connor CM (2004) Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Card Fail 10:258–271CrossRefPubMed
25.
Zurück zum Zitat Kato N, Kinugawa K, Shiga T, Hatano M, Takeda N, Imai Y, Watanabe M, Yao A, Hirata Y, Kazuma K, Nagai R (2012) Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction. J Cardiol 60:23–30CrossRefPubMed Kato N, Kinugawa K, Shiga T, Hatano M, Takeda N, Imai Y, Watanabe M, Yao A, Hirata Y, Kazuma K, Nagai R (2012) Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction. J Cardiol 60:23–30CrossRefPubMed
26.
Zurück zum Zitat Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM (2009) Pulmonary hypertension in heart failure with preserved ejection fraction. A community-based study. J Am Coll Cardiol 53:1119–1126CrossRefPubMedCentralPubMed Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM (2009) Pulmonary hypertension in heart failure with preserved ejection fraction. A community-based study. J Am Coll Cardiol 53:1119–1126CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Nath J, Vacek JL, Heidenreich PA (2006) A dilated inferior vena cava is a marker of poor survival. Am Heart J 151:730–735CrossRefPubMed Nath J, Vacek JL, Heidenreich PA (2006) A dilated inferior vena cava is a marker of poor survival. Am Heart J 151:730–735CrossRefPubMed
28.
Zurück zum Zitat Tanaka Y, Taniguchi M, Sugawara M, Nobusada S, Kusano K, Akagi T, Ito H (2013) Evaluation of exercise capacity using wave intensity in chronic heart failure with normal ejection fraction. Heart Vessels 28:179–187CrossRef Tanaka Y, Taniguchi M, Sugawara M, Nobusada S, Kusano K, Akagi T, Ito H (2013) Evaluation of exercise capacity using wave intensity in chronic heart failure with normal ejection fraction. Heart Vessels 28:179–187CrossRef
29.
Zurück zum Zitat Cournot M, Mourre F, Castel F, Ferrieres J, Destrac S (2008) Optimization of the use of b-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure. Am Heart J 155:986–991CrossRefPubMed Cournot M, Mourre F, Castel F, Ferrieres J, Destrac S (2008) Optimization of the use of b-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure. Am Heart J 155:986–991CrossRefPubMed
30.
Zurück zum Zitat Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P, Carbonieri E, Ceci V, Cerisano S, Barro S, Milani L (2005) B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 11:498–503CrossRefPubMed Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P, Carbonieri E, Ceci V, Cerisano S, Barro S, Milani L (2005) B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 11:498–503CrossRefPubMed
31.
Zurück zum Zitat West R, Liang L, Fonarow GC, Kociol R, Mills RM, O’Connor CM, Hernandez F (2011) Characteristics of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-international registry. Eur J Heart Fail 13:945–952CrossRefPubMedCentralPubMed West R, Liang L, Fonarow GC, Kociol R, Mills RM, O’Connor CM, Hernandez F (2011) Characteristics of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-international registry. Eur J Heart Fail 13:945–952CrossRefPubMedCentralPubMed
Metadaten
Titel
Risk factors for rehospitalization in heart failure with preserved ejection fraction compared with reduced ejection fraction
verfasst von
Masahiko Setoguchi
Yuji Hashimoto
Taro Sasaoka
Takashi Ashikaga
Mitsuaki Isobe
Publikationsdatum
01.09.2015
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 5/2015
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-014-0532-5

Weitere Artikel der Ausgabe 5/2015

Heart and Vessels 5/2015 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.